New Age Intervention® Enlighten by Jan Marini Skin Research

Brightens and Minimizes Discoloration of Facial Skin
Provides a More Refined, Resurfaced and Illuminated Facial Texture

San Jose, CA – Jan Marini Skin Research, Inc. (JMSR; www.janmarini.com) introduces Age Intervention Enlighten, a remarkable new composition that brightens and encourages the uniform appearance of facial discoloration — even stubborn hyperpigmentation.

“Women often associate fine lines and wrinkles with aging but discoloration is an even more visual sign of the aging process,” explains Jan Marini, president and CEO of Jan Marini Skin Research. “Age Intervention Enlighten is an exceptional brightening technology with de-aging agents that result in refined, rejuvenated and illuminated skin.”

Uneven skin tones and discoloration can age the look of facial skin just as dramatically as lines and wrinkles. Overly pigmented facial areas that may occur due to melasma, cumulative sun exposure and ethnicity are some of the most common and difficult to concerns to treat.

Enlighten contains a combination of two exceptional topical agents that address the appearance of facial discoloration. Enlighten also includes Retinol, a superior retinoid that discourages the production of excess melanin and assists in resolving the appearance of existing facial discoloration. The Retinol also acts as a potent anti-aging tool that provides a more refined, resurfaced and illuminated facial texture.

Enlighten’s exceptional brightening technology and de-aging agents result in the refined, rejuvenated and illuminated skin we all want.

Age Intervention Enlighten is offered in a 1 oz. pump bottle.

Jan Marini Skin Research
408.362.0130
www.janmarini.com

Source: Jan Marini Skin Research

BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology

Technology designed to selectively weaken specific muscles may provide an attractive alternative treatment for frown lines

San Mateo, CA – BioForm Medical, Inc. (NASDAQ: BFRM) announced that it has acquired substantially all of the assets of privately-held, Denver, CO based, Advanced Cosmetic Intervention, Inc. (ACI) and associated technology rights for $12 million cash, plus future royalties and a potential sales-related milestone. This acquisition provides BioForm Medical, a leading medical aesthetics company, with a commercially-available technology for local nerve ablation.

ACI’s device, sometimes also referred to as the GFX device in prior media reports, is currently cleared via a 510(k) by FDA to create RF heat lesions in nerve tissue. The ACI device uses minimally-invasive bi-polar radiofrequency energy selectively to weaken nerve signal transduction with durable effects.

The use of this technology on nerves that control the muscles of the forehead may reduce the appearance of frown lines, or glabellar furrows. BioForm Medical expects to conduct clinical studies specifically intended to support an FDA application seeking clearance to market this product for the treatment of frown lines. The Company expects to also seek a CE mark and certain other international registrations of the ACI device for aesthetics indications.

“We are building a leading medical aesthetics company. We believe this new treatment will offer patients an attractive alternative therapy for the treatment of frown lines. Many patients in our consumer research surveys have indicated that they choose not to receive neurotoxin treatment due to fear of losing facial expressions, or fear of injections with a toxin,” stated Steven Basta, CEO of BioForm Medical. “We believe that the synergy of this product with our Radiesse dermal filler will be terrific. We have a differentiated, long-lasting filler, and in the coming years we hope to offer physicians a new treatment option for frown lines. This is part of our commitment to partnering with physicians to offer them improved aesthetic treatment options that can grow their practices.

This device could appeal to many of the same physicians who select Radiesse dermal filler for their patients, and will leverage our existing sales and marketing organization.” In the acquisition of ACI, BioForm Medical will hire several of ACI’s employees, and retain others as consultants to maintain continuity of this program and to accelerate future product development and commercialization activities. In addition to the up-front consideration, BioForm Medical will pay a single-digit royalty to ACI. The Company anticipates that significant positive revenue impact of this acquisition is not likely until it obtains clearance for the product for aesthetic applications, anticipated to occur in calendar year 2009.

About BioForm Medical, Inc.
BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm’s products include Radiesse®, a long lasting filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite® for treating female stress urinary incontinence which is marketed through a partnership with Boston Scientific Corporation. BioForm has licensed U.S. marketing rights to Aethoxysklerol®, the worldwide leading sclerotherapy agent, which is currently being evaluated in a Phase III clinical trial. BioForm has also licensed BioGlue, a new surgical adhesive product for plastic surgery applications, which is being developed in a partnership with CryoLife, Inc.

BioForm Medical Inc.
866.862.1211
www.bioform.com

Source: BioForm Medical Inc.

Palomar Unveiled New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery

BURLINGTON, Mass. - Palomar Medical Technologies Inc. (Nasdaq: PMTI), a leading researcher and developer of light- based systems for cosmetic treatments, announced the unveiling its latest innovation in aesthetic laser technology at the 28th annual conference of the American Society for Laser Medicine & Surgery (ASLMS) in Kissimmee Florida, April 2-6. Palomar displayed a new platform called the Aspire(TM) aesthetic laser platform and Stylus(TM) Sculpter laser-assisted liposuction handpiece in booth #507 in the ASLMS exhibit hall. The Aspire platform will allow Palomar to offer solutions to new procedures which are in high-demand including laser-assisted liposuction. The Aspire platform will complement the broad range of aesthetic applications offered by Palomar’s flagship StarLux(R) 500 laser and pulsed-light platform.

Traditional liposuction is one of the most commonly performed plastic surgery procedures, according to the 2007 survey from the American Society of Aesthetic Plastic Surgery. Laser-assisted liposuction holds out the promise for a better technique due to the laser’s ability to quickly and selectively melt fat and heat surrounding tissue. Palomar’s approach to laser-assisted liposuction with the Aspire platform and Stylus Sculpter handpiece is to utilize unique tip designs and selective and efficient wavelengths for melting fat and providing the desired thermal effects on surrounding tissue.

Chief Executive Officer Joseph P. Caruso commented, “The unveiling of the Aspire platform and Stylus Sculpter handpiece is the culmination of years of research directed to absorption of light by fat. Our system uses optimal wavelengths to melt fat and provide the appropriate amount of heat to the surrounding tissue. As with all Palomar products, the Aspire platform is based on sound scientific principles developed and tested by Palomar’s research and development organization, which is preeminent in the light-based aesthetic industry.”

Mr. Caruso continued, “The Aspire platform is an ideal complement to the StarLux platform for providing opportunities for even more treatment modalities. With the new aesthetic procedures that will be possible with Aspire, and the many popular treatments, including hair removal, skin rejuvenation and skin resurfacing, available with the StarLux(R) 500, practitioners will be able to offer a complete suite of the most-requested aesthetic procedures.”

The Aspire Platform and Stylus Sculpter liposuction laser-assisted handpiece are pending FDA clearance and should be available for shipment in the third quarter 2008.

About Palomar Medical Technologies Inc.
Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the- counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

Palomar Medical
800.PALOMAR (725.6627)
www.palomarmedical.com

Source: Palomar Medical

Bio-Therapeutic Presents the bt-analyze™

Bio-Therapeutic is pleased to release the bt-analyze™ skin identification system. Part of Bio-Therapeutic’s bt-gear™ line, the bt-analyze™ provides an accurate and essential assessment of the skin’s moisture contents.

The bt-analyze™ is tiny in price and size, but large on performance. Measuring less than 3.5 inches in length the bt-analyze™ weighs less than ¼ of a pound and holds a minuscule price of $95 making it an ideal fit for all forward thinking technologists looking to get their tech on!

Bio-Therapeutic, Inc., the world leader in anti-aging technology, was established in 1974, and is headquartered in Seattle, Washington. With worldwide distribution, Bio-Therapeutic supplies skin therapists with the most cutting edge, age defying technology available today including the Bio-Ultimate Platinum® microcurrent system, Bio-Synthesis™ light activated rejuvenation system, Bio-Oxygen™ oxygen infusion system, Bio-Brasion™ microdermabrasion system, Bio-Dermology™ cellulite system, and bt-GEAR™ Tools and Technology of Convenience. The company is a FDA and ISO registered device manufacturer, and all equipment is safety tested and UL/CSA listed. Ongoing clinical trials with the University of Washington ensure proven efficacy and results.

Bio-Therapeutic
800.971.6438
www.bio-therapeutic.com

Source: Bio-Therapeutic

Artes Medical plans to restructure to cut costs

Artes Medical plans to restructure but will still expand its ArteFill sales force

NEW YORK (Associated Press) - Medical technology company Artes Medical Inc. said it is restructuring in an effort to reduce costs in line with expected revenue.

The company said the goal is to “re-align” its overall cost structure toward its prior 2008 revenue guidance of $13 million to $16 million. Meanwhile, it will continue expanding its sales force for the injectable implant ArteFill, which is used as a wrinkle treatment.

Artes said it believes it has enough cash, along with anticipated ArteFill sales, to fund the company through the first quarter of 2009.

Shares of Artes fell 8 cents, or 6.7 percent, to close at $1.12.

Artes Medical
888.ARTEFILL (278.3345)
www.artesmedical.com

Source: CNN Money